Home › NDC Lookup › RxCUI directory › RxCUI 2714659

Treprostinil 0.0265 MG Inhalation Powder — RxCUI 2714659

RxNorm drug concept · Semantic clinical drug
RxCUI 2714659 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2714659
Official nameTreprostinil 0.0265 MG Inhalation Powder
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astreprostinil 26.5 MCG Inhalation Powder; treprostinil 26.5 MCG (equivalent to treprostinil sodium 28 MCG) Inhalation Powder
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)174 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Treprostinil Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Treprostinil injection — sold as Remodulin — is used to treat pulmonary arterial hypertension, or PAH. That's a condition where the blood pressure inside the arteries leading to yo...
  • What exactly is treprostinil injection used for?
  • No — treprostinil injection is given as a continuous infusion that runs around the clock, usually through a small pump you wear. Most people receive it through a tiny catheter plac...
  • How is this medication given? Do I have to go to a clinic for every dose?
📖 Read our full Treprostinil Injection guide →

🕸️ Concept Web — How Treprostinil 0.0265 MG Inhalation Powder Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Treprostinil 0.0265 MG Inhalation Powder RxCUI 2714659

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Treprostinil 343048
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Yutrepia 2714660
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Treprostinil Inhalation Powder 2602750
    • Treprostinil Inhalant Product 1157681
    • Treprostinil Inhalation Powder [Yutrepia] 2714663
    • Yutrepia Inhalant Product 2714662
    • Inhalation Powder 317000
    • Inhalant Product 1151123
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Treprostinil 0.0265 MG SCDC · 2714658
  • Treprostinil Inhalation Powder SCDF · 2602750
  • Treprostinil Inhalant Product SCDG · 1157681

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2714659 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72964-0011-01 7 BLISTER PACK in 1 CARTON (72964-011-01) / 4 CAPSULE in 1... Yutrepia Liquidia Technologies, Inc. 2025-05-23
72964-0012-01 7 BLISTER PACK in 1 CARTON (72964-012-01) / 4 CAPSULE in 1... Yutrepia Liquidia Technologies, Inc. 2025-05-23
72964-0013-01 7 BLISTER PACK in 1 CARTON (72964-013-01) / 4 CAPSULE in 1... Yutrepia Liquidia Technologies, Inc. 2025-05-23
72964-0014-01 7 BLISTER PACK in 1 CARTON (72964-014-01) / 4 CAPSULE in 1... Yutrepia Liquidia Technologies, Inc. 2025-05-23
Observed labelers: Liquidia Technologies, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.